Safety of Adjuvant Oral Uracil-Tegafur Therapy in Older Patients With Resected Non-small Cell Lung Cancer

Background/Aim: Oral uracil-tegafur (UFT) therapy as adjuvant chemotherapy (ACT) has demonstrated efficacy and is widely used for patients with completely resected early-stage non-small cell lung cancer (NSCLC). However, most previous clinical trials have enrolled patients aged ≤75 years, and evidence regarding the safety of UFT in older patients remains limited. This study aimed to evaluate the safety of adjuvant UFT therapy in older patients. Patients and Methods: We retrospectively analyzed 101 patients who underwent curative lung resection and were pathologically diagnosed with stage IA3 or IB NSCLC (TNM 8th edition) at our department between January 2017 and January 2023. Patients were stratified into older (aged ≥75 years) and younger (aged